Johnson Fistel Investigates Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on Behalf of Investors

Johnson Fistel is investigating Unicycive Therapeutics after the FDA issued a second Complete Response Letter on June 30, 2026, citing the same third-party manufacturing deficiencies from a prior CRL. The FDA had not yet inspected the manufacturing vendor at the time of the resubmission. The announcement led to a decline in Unicycive's stock price, prompting investigation into potential false or misleading statements.